The maintained Buy rating suggests that HC Wainwright & Co. still sees potential in Iovance Biotherapeutics, which could be positive for investor sentiment. However, the reduction in the price target may indicate some concerns about the company's future growth or market conditions, which could temper investor enthusiasm. The net impact on the stock price is uncertain, as the positive and negative news could offset each other in the short term.